Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Extended-Release Drugs Market Expected To Expand Between 2025 And 2029?
The market size for extended-release drugs has witnessed significant expansion in recent years. This market is expected to increase from $63.11 billion in 2024 to $69.63 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.3%. The historical growth of this market can be linked to several factors, including enhanced patient compliance, the rising prevalence of chronic diseases, improvements in drug efficacy, effective patent protection strategies, and the introduction of biodegradable implants.
The extended-release drugs market size is anticipated to undergo significant growth in the coming years. It is projected to reach $111.26 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.4%. This expansion during the forecast period is attributed to factors such as personalized medicine approaches, patient-centric drug development, a rising incidence of lifestyle diseases, drug repurposing efforts, and enhanced global access to extended-release therapies. Key trends expected in this period include continued pharmaceutical innovation, advancements in drug delivery systems, progress in nanotechnology, the application of 3D printing in drug formulations, the increasing use of artificial intelligence, and a focus on environmental sustainability.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp
Which Drivers Are Supporting Growth Of The Extended-Release Drugs Market?
The rising prevalence of chronic health issues is anticipated to stimulate the expansion of the extended-release drug market moving forward. Chronic conditions are identified as illnesses persisting for a year or longer, necessitating continuous medical supervision, impacting daily routines, or both. Heart disease, cancer, obesity, and diabetes serve as illustrative examples. Extended-release drug delivery mechanisms are formulated to ensure a relatively stable concentration of medication within the body over an extended timeframe. This method helps in sustaining a consistent therapeutic outcome and prevents the fluctuations in drug levels that can occur with immediate-release medications. For instance, in January 2023, data from the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, indicated that by the year 2050, the number of individuals aged 50 years and older suffering from at least one chronic illness is projected to climb by 99.5%, reaching 142.66 million. Therefore, the increasing occurrence of chronic conditions is fueling the growth of the extended-release drug market.
What Are The Primary Types Of Segments Analyzed In The Extended-Release Drugs Market?
The extended-release drugs market covered in this report is segmented –
1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores
Subsegments:
1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems
Which Ongoing Trends Are Expected To Shape The Extended-Release Drugs Market Outlook?
Product innovation represents a significant trend gaining traction within the extended-release drug market. Major companies operating in the extended-release drug market are developing inventive products to sustain their competitive position. For instance, in July 2022, Zydus Pharmaceuticals (USA) Inc., a US-based generic pharmaceutical manufacturer, introduced Topiramate extended-release capsules for epilepsy. The US Food and Drug Administration (USFDA) had previously approved the company for the commercialization of Topiramate extended-release capsules, USP, in strengths of 25 mg, 50 mg, and 100 mg. This company is notably the first in the country to secure final approval and launch Topiramate extended-release capsules. Topiramate extended-release tablets hold two approvals for individuals experiencing partial onset or primary generalized tonic-clonic seizures.
Who Are The Prominent Global Companies Shaping The Extended-Release Drugs Market?
Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report
What Are The Key Regional Factors Influencing The Extended-Release Drugs Market Growth?
North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Extended-Release Drugs Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12675&type=smp
Browse Through More Reports Similar to the Global Extended-Release Drugs Market 2025, By The Business Research Company
Extended Reality Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/extended-reality-global-market-report
Drugs Of Abuse Doa Testing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/drugs-of-abuse-doa-testing-global-market-report
Drugs For Benign Prostatic Hypertrophy Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
